Your browser is no longer supported. Please, upgrade your browser.
Settings
NVS Novartis AG daily Stock Chart
NVS [NYSE]
Novartis AG
Index- P/E30.65 EPS (ttm)2.66 Insider Own9.30% Shs Outstand2.61B Perf Week1.93%
Market Cap212.83B Forward P/E15.67 EPS next Y5.20 Insider Trans0.17% Shs Float2.53B Perf Month6.77%
Income6.37B PEG5.55 EPS next Q1.18 Inst Own11.60% Short Float0.18% Perf Quarter5.10%
Sales49.41B P/S4.31 EPS this Y-2.80% Inst Trans7.16% Short Ratio1.73 Perf Half Y16.07%
Book/sh28.49 P/B2.86 EPS next Y10.18% ROA4.80% Target Price85.75 Perf Year3.80%
Cash/sh- P/C- EPS next 5Y5.52% ROE8.80% 52W Range66.93 - 83.58 Perf YTD11.75%
Dividend2.72 P/FCF82.49 EPS past 5Y-5.80% ROI7.30% 52W High-2.60% Beta0.76
Dividend %3.34% Quick Ratio0.70 Sales past 5Y-3.60% Gross Margin65.30% 52W Low21.63% ATR0.90
Employees118000 Current Ratio1.00 Sales Q/Q-0.20% Oper. Margin15.50% RSI (14)74.31 Volatility0.86% 0.85%
OptionableYes Debt/Eq0.46 EPS Q/Q-16.80% Profit Margin12.90% Rel Volume0.36 Prev Close81.40
ShortableYes LT Debt/Eq0.34 EarningsApr 25 BMO Payout101.50% Avg Volume2.61M Price81.40
Recom2.00 SMA202.90% SMA506.72% SMA2008.02% Volume914,239 Change0.01%
Mar-09-17Initiated Liberum Buy
Mar-08-17Upgrade Societe Generale Hold → Buy
Mar-07-17Downgrade Exane BNP Paribas Neutral → Underperform
Jan-11-17Downgrade Credit Suisse Outperform → Neutral
Nov-10-16Upgrade Argus Hold → Buy
Oct-10-16Reiterated Chardan Capital Markets Buy $95 → $92
Sep-20-16Initiated Chardan Capital Markets Buy $95
Apr-12-16Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-23-16Downgrade Leerink Partners Outperform → Mkt Perform
Jun-22-15Upgrade Bryan Garnier Neutral → Buy
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-26-09Initiated Jefferies & Co Hold
Sep-23-08Upgrade Credit Suisse Underperform → Neutral
Aug-06-08Downgrade JP Morgan Overweight → Neutral
May-25-17 10:36AM  Could There Be a Revenue Fall for Neulasta in 2017? Market Realist
07:43AM  Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline Zacks
07:11AM  Novartis (NVS) Reports Positive Data on Ultibro Breezhaler Zacks
May-24-17 04:45PM  Cambridge largely spared as Novartis cuts hundreds of jobs American City Business Journals
10:37AM  Neupogen and Enbrel Could See Falling Revenues in 2017 Market Realist
07:00AM  Wide-Moat Roche Is Undervalued Morningstar
May-23-17 08:59AM  The Current State Of The Breast Cancer Treatment Space Benzinga
May-22-17 05:53PM  Novartis' (NVS) Lung Cancer Drug Gets Positive CHMP Opinion Zacks
04:57PM  Biotech And Pharma Industry And Stock News Investor's Business Daily
04:15PM  Will Novartis' MS Drug Stomp Celgene's Before It Even Hits The Market? Investor's Business Daily
May-19-17 10:20AM  Amgen (AMGN) Submits BLA to FDA for Migraine Drug Erenumab Zacks
08:38AM  CHMP backs Novartis's Zykadia for first-line use in lung cancer Reuters
May-18-17 03:44PM  Conference Spotlights Drug Giant Donnybrooks In Cancer Treatments Investor's Business Daily
09:48AM  Novartis to cut around 500 jobs in Switzerland, add 350 Reuters
May-17-17 02:16PM  Aduro Biotech, Merch Team on Cancer Drug Trial TheStreet.com
May-16-17 08:00AM  Today's Research Reports on Stocks to Watch: GlaxoSmithKline and Novartis Accesswire
May-15-17 08:27AM  GlaxoSmithKline Could Buy Out Partner Novartis TheStreet.com
May-12-17 04:20PM  Can Teva Hold Its Own In Bringing Migraine Drugs To Market? Investor's Business Daily
May-08-17 08:46AM  Pharma Stock Roundup: Merck, Pfizer Report Q1 Earnings, J&J Talc Powder Lawsuit Zacks
07:00AM  DURECT and Sandoz have Signed a $293 Million Development and Commercialization Agreement for POSIMIR® (SABER®-Bupivacaine) Covering the United States PR Newswire
May-07-17 02:06PM  Barron's Picks And Pans: Amazon, Novartis, Tesla And More Benzinga
May-06-17 12:53AM  [$$] Novartis Has the Right Prescription for Profits Barrons.com
May-05-17 11:06AM  Conatus (CNAT) Q1 Loss Narrows Y/Y, Revenues Beat Estimates Zacks
08:15AM  Blog Coverage: Novartis Exercises Option for Global Development and Commercialization of Conatus Pharmaceuticals' Drug Emricasan Accesswire
May-04-17 10:48AM  Ophthotech (OPHT) Q1 Loss Narrower than Expected, Sales Miss Zacks
02:56AM  Novartis, Roche back French gene therapy start-up Vivet Reuters
01:51AM  Novartis exercises option with Conatus for NASH product Reuters
May-03-17 10:33AM  Bristol-Myers: Going Stag to the Ball? Barrons.com
May-02-17 04:27PM  Dow's Pfizer Tops Earnings Views, But Sales Come Up Short Investor's Business Daily
11:10AM  Cambridge's bluebird bio licenses delivery tech to Novartis, GSK American City Business Journals
09:07AM  How GlaxoSmithKlines Vaccines Business Performed in 1Q17 Market Realist
07:35AM  Stem cell biotech Magenta bags $50M, strikes licensing deal with Novartis American City Business Journals
May-01-17 04:13PM  ETFs with exposure to Novartis AG : May 1, 2017 Capital Cube
07:40AM  How GlaxoSmithKlines Business Segments Performed in 1Q17 Market Realist
07:37AM  Novartiss Valuation after 1Q17 Earnings Market Realist
Apr-30-17 04:00PM  How Far Into the Drug Pipeline Should the FTC Reach? TheStreet.com
11:41AM  5 Big Drugmakers With Important Catalysts in May Motley Fool
Apr-28-17 01:08PM  U.S. FDA approves Novartis' leukemia treatment Reuters
12:01PM  [$$] Biotech and big pharma reap rewards from partnerships Financial Times
11:13AM  Novartis AG :NVS-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017 Capital Cube
10:37AM  Novartiss 1Q17 Earnings: Recent Developments Market Realist
10:21AM  U.S. FDA approves Novartis' leukemia treatment Reuters
09:08AM  1Q17 Earnings for Novartiss Alcon, Its Eye Care Business Market Realist
08:41AM  Pharma Stock Roundup: Lilly, Bristol-Myers, Novartis Q1 Earnings & More Zacks
07:39AM  1Q17 Earnings for Novartiss Sandoz, Its Generics Business Market Realist
Apr-27-17 05:05PM  Novartiss 1Q17 Earnings: Innovative Medicines Segment Market Realist
03:36PM  Novartiss 1Q17 Earnings: Segment Performances Market Realist
02:01PM  Why Novartiss 1Q17 Revenues Missed Analysts Estimates Market Realist
Apr-26-17 02:19PM  U.S. top court grapples over making copycat biologics available sooner Reuters
12:46PM  Jerome Dodson Comments on Novartis GuruFocus.com
12:23PM  U.S. top court debates making copycat biologics available sooner Reuters
09:11AM  Glaxo (GSK) Beats Earnings and Revenues in Q1 Zacks
07:36AM  GlaxoSmithKlines 1Q17 Estimates: Vaccines Business Market Realist
Apr-25-17 04:45PM  Novartis Earnings Top, But Sales Dip Despite New Blockbuster Drug Investor's Business Daily
03:46PM  Novartis, Amgen Divvy Global Marketing of New Migraine Drug TheStreet.com
01:53PM  Novartis Tops Q1 Earnings: Cosentyx, Entresto Boost Sales Zacks
12:01PM  Novartis to speed up bid for MS drug approval, changes target Reuters
11:39AM  Novartis sets sights on return to growth in 2018 Reuters
09:09AM  GlaxoSmithKlines 1Q17 Estimates: Revenues Expected to Grow Market Realist
08:28AM  Stock Futures See More Gains on a Stream of Positive Earnings TheStreet.com
08:22AM  Will Low Pricing for Siliq Be Enough to Help Valeant Turn Things Around? Motley Fool
06:00AM  Novartis beats 1Q profit forecasts Associated Press
05:56AM  Swiss drugs giant Novartis posts 15 percent drop in profit Associated Press
05:56AM  Novartis Shares Jump After Group Holds To Full Year Forecasts; Sees Entresto Growth TheStreet.com
02:59AM  [$$] Novartis Profit Dented by Investment in New Drugs The Wall Street Journal
01:26AM  Novartis Moves M&A Search to Early-Stage Drugs on Price Gain Bloomberg
Apr-24-17 04:14PM  How Lilly's New Drug Could Spark A Deeper Rivalry With Pfizer, Novartis Investor's Business Daily
10:37AM  Analyst Ratings and Recommendations for Novartis Market Realist
07:38AM  Novartiss 1Q17 Estimates for Sandoz Market Realist
05:52AM  Drug Stocks Q1 Earnings Releases on Apr 25: LLY, BIIB, NVS Zacks
12:02AM  Novartis Tests New Alzheimers Drug on People Who Dont Have the Disease The Wall Street Journal
Apr-23-17 06:15PM  Novartis Tests New Alzheimer's Drugs on People Who Don't Have the Disease The Wall Street Journal
11:41AM  Should Gilead Sciences Be Worried About Allergan? Motley Fool
Apr-21-17 04:35PM  Novartiss 1Q17 Estimates: Innovative Medicines Segment Market Realist
03:05PM  Analysts Expect Novartiss Revenues to Remain Flat in 1Q17 Market Realist
01:13PM  Analyst Estimates for Novartiss 1Q17 Earnings Market Realist
12:25PM  Three Hot Junior Biotech Plays Investopedia
07:12AM  Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL Zacks
Apr-20-17 01:40PM  An Alcon Sale Will Take a Bargain Price Bloomberg
10:19AM  Novartis (NVS) Q1 Earnings: Will the Stock Disappoint? Zacks
Apr-19-17 11:47AM  Novartis AG : NVS-US: Dividend Analysis : March 03rd, 2017 (record date) : By the numbers : April 19, 2017 Capital Cube
10:11AM  Allergan (AGN) Collaborates with Novartis to Treat NASH Zacks
10:01AM  Novartis' (NVS) CTL109 BLA Gets Breakthrough Therapy Status Zacks
Apr-18-17 04:36PM  Could Lilly Outperform These Bigger Rivals On Strong Diabetes Meds? Investor's Business Daily
12:22PM  Why the Ionis Spinoff Will Be a Win for Long-Term Investors Motley Fool
07:09AM  Novartis Predicts Chinese Drug Market Growth Will Accelerate Bloomberg
07:05AM  Novartis Snags Coveted FDA 'Breakthrough' Label for CAR-T, Trial Results Still Under Wraps TheStreet.com
05:51AM  Novartis CEO Says Trump Discussed Pricing With Drug CEOs Bloomberg Video
05:37AM  Novartis CEO Says Pharma Needs to Step Up Its Efforts Bloomberg Video
04:07AM  Novartis advances with push on cancer and liver disease Reuters
03:09AM  Novartis (NVS) Up 7.7% Since Earnings Report: Can It Continue? Zacks
Apr-17-17 05:56PM  10 Most Profitable Companies In Europe Insider Monkey
01:11PM  Jerome Dodson Buys 2 Stocks, Sells 2 in 1st Quarter GuruFocus.com
Apr-13-17 04:21PM  Here's Why the Best Is Yet to Come for Ionis Pharmaceuticals, Inc. Motley Fool
Apr-11-17 09:17AM  Forget Novartis, Buy These Two Pharma Stocks Instead Zacks
Apr-09-17 07:22AM  5 Pharmaceutical Stocks With the Most Reliable Dividends Motley Fool
Apr-08-17 09:43AM  Why Juno Therapeutics Stock Slumped in March Motley Fool
07:22AM  3 Big Pharma Companies With the Best Pipelines Motley Fool
Apr-07-17 05:03PM  Novartis (NVS) In-Licenses Ophthalmic Drug from Lubris LLC Zacks
01:38PM  Analysts Release New Health Care Stock Ratings GuruFocus.com
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Innovative Medicines, Sandoz, and Alcon. The Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. It franchises ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic, and other medicines, as well as cell and gene therapies. The Sandoz segment offers active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The Alcon segment offers eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses for use in surgical procedures to treat cataracts, vitreoretinal conditions, glaucoma, and refractive errors; and contact lenses and lens care products. The company has collaboration and licensing agreements with Xencor for the development of bispecific antibodies for treating cancer; and with Surface Oncology to access four pre-clinical programs in immuno-oncology. It also has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and Caribou Biosciences for the development of drug discovery tools. The company was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerMay 18Sale25.509,019229,9642,409,403May 22 06:50 PM
Novartis Bioventures Ltd10% OwnerMay 17Sale25.5122,534574,9012,418,422May 18 04:36 PM
Novartis Bioventures Ltd10% OwnerMay 16Sale26.3320,081528,7252,440,956May 18 04:36 PM
Novartis Bioventures Ltd10% OwnerMar 15Buy5.00560,0002,800,0005,805,550Mar 17 08:36 PM
Novartis Bioventures Ltd10% OwnerMar 01Sale20.917,778162,6582,461,037May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 28Sale20.867,847163,6702,468,815May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 27Sale20.9657,8441,212,3062,476,662May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 24Sale20.935,398113,0002,534,506May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 23Sale21.044,999105,1602,539,904May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 22Sale21.8674916,3702,544,903May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerOct 31Buy13.0084,6151,099,9952,545,652Oct 31 04:50 PM
Novartis Bioventures Ltd10% OwnerOct 31Sale13.003394,40762,575Oct 31 04:50 PM